Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Bryan D. Marks"'
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 1469K, Different ABL TKIs demonstrate potency differences in relative cellular and biochemical target inhibition (S1); Incomplete restoration of BCR-ABL signaling activity following washout of dasatinib or ponatinib tracks with intracellul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45bb2f349dbdbd12daa46b5865710272
https://doi.org/10.1158/0008-5472.22396247
https://doi.org/10.1158/0008-5472.22396247
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 337K, Summary of mean fluorescence intensity values for levels of CrkL and STAT5 phosphorylation in K562 cells following acute ABL TKI exposure followed by standard and expanded washout (S1); Kinase:inhibitor dissociation off-rates for ABL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464ff7a97c638799f3fd2f9fd2378704
https://doi.org/10.1158/0008-5472.22396238.v1
https://doi.org/10.1158/0008-5472.22396238.v1
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 45K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2e7b60dba00e64f41fe83e32b81c9f
https://doi.org/10.1158/0008-5472.22396250.v1
https://doi.org/10.1158/0008-5472.22396250.v1
Autor:
Hildegard C. Eliason, Stephen A. Fakhoury, William J. Frazee, Steven M. Riddle, Bryan D. Marks
Publikováno v:
SLAS Discovery. 16:1247-1253
Developing molecularly targeted therapeutics with minimal off-target effects is facilitated by an understanding of compound selectivity. However, for HDAC inhibitors, a clear understanding of specificity has been challenging. In particular, it has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ae812ddd8ee17f996ef878fdf0bad0
https://doi.org/10.1177/1087057111422102
https://doi.org/10.1177/1087057111422102
Publikováno v:
Letters in Drug Design & Discovery. 5:416-422
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36478c2a37b72a0dec12e45dc6469f2e
https://doi.org/10.2174/157018008785777261
https://doi.org/10.2174/157018008785777261
Autor:
Krishne Gowda, Naveeda Qadir, Mary Szatkowski Ozers, Kerry M. Ervin, Kevin R. Kupcho, Bryan D. Marks, Mohammed Saleh Shekhani, Therese De Rosier, Hildegard C. Eliason, Steven M. Riddle
Publikováno v:
Biochemistry. 46:683-695
The interactions of the ligand binding domain (LBD) of androgen receptor (AR) and the AR T877A mutant, found in prostate cancer, with peptides from coactivator and corepressor proteins or random phage display peptides were investigated using in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc3c90814d4c9823706911db48b0af09
https://doi.org/10.1021/bi061321b
https://doi.org/10.1021/bi061321b
Autor:
Kurt W. Vogel, Dennis R. Koop, Lauren T. Adrian, Dorian LaTocha, Ryan MacKenzie, Brian J. Druker, Huihong You, Thomas O'Hare, Jeffrey W. Tyner, Jenny Luo, Bryan D. Marks, Matthew S. Zabriskie, Kara Johnson, Anupriya Agarwal, Steven M. Riddle, Christopher A. Eide, John Apgar, Michael W. Deininger
The imatinib paradigm in chronic myelogenous leukemia (CML) established continuous BCR-ABL inhibition as a design principle for ABL tyrosine kinase inhibitors (TKI). However, clinical responses seen in patients treated with the ABL TKI dasatinib desp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b35458dd3e7d2c4be9b2f453e74d7d
https://europepmc.org/articles/PMC3674150/
https://europepmc.org/articles/PMC3674150/
Autor:
Yi Gao, Kurt W. Vogel, Hildegard C. Eliason, Connie S. Lebakken, Steven M. Riddle, Laurie J. Reichling, Bryan D. Marks, W. Jack Frazee, Upinder Singh
Publikováno v:
Journal of biomolecular screening. 14(8)
The expansion of kinase assay technologies over the past decade has mirrored the growing interest in kinases as drug targets. As a result, there is no shortage of convenient, fluorescence-based methods available to assay targets that span the kinome.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1d2776d73b22a4e5c18679a16a4850
https://pubmed.ncbi.nlm.nih.gov/19564447
https://pubmed.ncbi.nlm.nih.gov/19564447
Autor:
Sunita J. Shukla, Anton Simeonov, James Inglese, William J. Frazee, John Printen, Hildegard C. Eliason, Ryan MacArthur, Christopher P. Austin, Bryan D. Marks, Tina M. Hallis, Douglas S. Auld, Upinder Singh, Dac-Trung Nguyen
The human pregnane X nuclear receptor (PXR) is a xenobiotic-regulated receptor that is activated by a range of diverse chemicals, including antibiotics, antifungals, glucocorticoids, and herbal extracts. PXR has been characterized as an important rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5a71bbfd9868b23ee45e6e3cee5ecf0
https://europepmc.org/articles/PMC3116688/
https://europepmc.org/articles/PMC3116688/
Autor:
Maya Fuerstenau-Sharp, David R. Piper, Steve Duff, Stephen D. Hess, Pam Whitney, Mohammed Saleh Shekhani, C. Jachec, W. Jack Frazee, Hildegard C. Eliason, Kurt W. Vogel, Bryan D. Marks, Elizabeth A. Frey, Brian A. Pollok, David V. Thompson
Publikováno v:
Assay and drug development technologies. 6(2)
The life-threatening consequences of acquired, or drug-induced, long QT syndrome due to block of the human ether-a-go-go-related gene (hERG) channel are well appreciated and have been the cause of several drugs being removed from the market in recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70cebf6643f4d2882c6f2b5a7fa437fa
https://pubmed.ncbi.nlm.nih.gov/18471075
https://pubmed.ncbi.nlm.nih.gov/18471075